title: Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
authors.affiliation: Department of Internal Medicine, University of Cologne, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Fätkenheuer
authors.forename: K
authors.initials: K
authors.lastname: Römer
authors.forename: R
authors.initials: R
authors.lastname: Kamps
authors.forename: B
authors.initials: B
authors.lastname: Salzberger
authors.forename: D
authors.initials: D
authors.lastname: Burger
mesh_terms: D019380:Anti-HIV Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D002219:Carbamates; D005663:Furans; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D061466:Lopinavir; D019829:Nevirapine / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000493:pharmacokinetics* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013449:Sulfonamides / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D061466:Lopinavir; C095108:amprenavir; D019829:Nevirapine